We analyzed the outcomes of 61 patients with hematologic malignancies who underwent double-unit cord blood transplantation (dCBT) after myeloablative conditioning performed as part of a prospective multicenter phase II study. The conditioning regimen for dCBT included total body irradiation, cyclophosphamide, and granulocyte colony-stimulating factor combined with cytosine arabinoside for myeloid malignancies and with total body irradiation and cyclophosphamide for lymphoid malignancies. The cumulative incidence of neutrophil engraftment after dCBT was 85% (95% confidence interval [CI], 73%-92%). All 51 of the patients who engrafted had complete chimerism derived from a single donor by day þ60. Only the degree of HLA disparity in the host-versus-graft direction had an impact on unit dominance. The cumulative incidence of grade II-IV acute graft-versus-host disease was 25% (95% CI, 15%-37%), and that of chronic graft-versus-host disease was 32% (95% CI, 20%-44%). The 1-year cumulative incidence of relapse was 23% (95% CI, 13%-34%), and that of transplantation-related mortality was 28% (95% CI, 17%-39%). With a median follow-up of 41 months, eventfree survival was 48% (90% CI, 37%-58%) at 1 year and 46% (90% CI, 35%-56%) at 3 years. Event-free survival at 3 years was 67% (95% CI, 46%-81%) for patients with standard risk and 29% (95% CI, 15%-45%) for those with advanced risk. This study suggests that dCBT after myeloablative conditioning is a promising alternative for adults and large children with hematologic malignancies who need stem cell transplantation but lack a suitable adult donor or an adequate single-unit cord blood graft. Ó
INTRODUCTION
Cord blood (CB) is being increasingly used as an alternative source of hematopoietic stem cells for adults with hematologic malignancies requiring hematopoietic stem cell transplantation (HSCT) [1] [2] [3] [4] [5] . Although CB has advantages, including rapid availability [6] and low risk of severe acute graft-versus-host disease (GVHD) despite HLA mismatches, the low cell dose in a single CB unit contributes to high rates of graft failure and transplantation-related mortality (TRM), especially in adults and large children [7] [8] [9] . Double-unit CB transplantation (dCBT) was introduced to overcome these obstacles [10] and is becoming more widely applied [11] [12] [13] [14] [15] . We conducted a prospective multicenter Phase II study assessing the safety and efficacy of dCBT for patients with high-risk hematologic malignancies. We used relatively standard myeloablative conditioning regimens: total body irradiation (TBI) plus cyclophosphamide (CY) for lymphoid malignancies and TBI, CY, and granulocyte colonystimulating factor (G-CSF) combined with cytosine arabinoside (ara-C) for myeloid malignancies. We used cyclosporine A (CyA) and short-term methotrexate (MTX) for GVHD prophylaxis.
PATIENTS AND METHODS
Thirty-nine centers participated in this study after approval by each pertinent Institutional Review Board (trial identifier: UMIN: C000000359, C-SHOT 0507). Written informed consent was obtained from all patients before transplantation.
Eligibility Criteria
Inclusion criteria were as follows: (1) age <55 years with a high-risk hematologic malignancy; (2) no HLA-matched or single antigenmismatched related donor available; (3) no HLA-matched unrelated donor available, or requiring urgent transplantation even if an HLA-matched unrelated donor were available; (4) no 4-6/6 HLA-A, -B, or -DR serologically antigen-matched single CB unit containing a cell dose >2.5 Â 10 7 /kg; (5) no previous stem cell transplantation; (6) no active infection at the start of conditioning chemoradiotherapy; and (7) HIV-negative status. Patients with an Eastern Cooperative Oncology Group performance status !2, ejection fraction <50%, SaO 2 (arterial oxygen saturation) <93% in room air, serum creatinine of !1.3 mg/dL, total bilirubin !1.6 mg/dL, or glutamicoxaloacetic transaminase !2 times the normal value were excluded. Patients with Down syndrome or Fanconi anemia were also excluded. E-mail address: kai@hyo-med.ac.jp (S. Kai).
CB Unit Selection Criteria CB units were obtained from CB banks belonging to the Japan Cord Blood Bank Network. The criterion for CB unit selection was 4-6/6 HLA-A, -B, and -DR antigens matched to the recipient. One of the 2 units should contain a cell dose of at least 1.5 Â 10 7 /kg. The total cell dose of the 2 units had to be >2.5 Â 10 7 /kg, and transplantation of 2 units each with a cell dose >2 Â 10 7 / kg was not allowed.
Treatment
All patients received a myeloablative preparative conditioning regimen of 12 Gy TBI fractionated in 4 or 6 doses. Ara-C was given at a dose of 3 g/m 2 every 12 hours for 2 days (days -5 and -4). Recombinant human G-CSF was given by continuous infusion at a dose of 5 mg/kg/day; infusion was started at 12 hours before the first dose of ara-C and stopped at the completion of the last dose. CY was administered i.v. at 60 mg/kg/day for 2 days (days -3 and -2). A regimen of TBI, CY, and G-CSF combined with ara-C was used for patients with myeloid leukemias and myelodysplastic syndrome (MDS) [1] . TBI plus CY was used for those with lymphoid malignancies. At 2 days after completion of conditioning, CB units were thawed and then infused sequentially in an arbitrary order and nonmandatory time interval after premedication with hydrocortisone (100 mg) and hydroxyzine hydrochloride (25 mg).
GVHD prophylaxis was provided with CyA plus short-term MTX. CyA was given by continuous infusion at a dose of 3 mg/kg/day starting on day -1. MTX was given at 15 mg/m 2 i.v. on day þ1 and at 10 mg/m 2 on days þ3
and þ6. Once oral intake could be tolerated, oral CyA was started at a dose ratio of 1:2.5 in 2 divided doses per day based on the last i.v. dose. In the absence of GVHD after day þ60, CyA was tapered by 10% to 20% per week until it could be discontinued. The supportive care regimen, including prophylaxis for infection, was similar to that for single-unit CBT in each transplantation center. All patients received G-CSF starting on day 5 and continuing until the absolute neutrophil count (ANC) reached 5000/mL.
HLA Typing and Chimerism Analysis
HLA typing of the recipient and CB unit was determined by lowresolution (2 digits) and/or high-resolution (4 digits) DNA typing for HLA-A, -B, -C, and -DRB1. Donor chimerism was determined serially for bone marrow and/or blood at days þ14, þ30, þ60, and þ100 after dCBT, and at additional time points as needed. The analytic method used was based on the quantitative amplification of informative polymorphic short tandem repeat regions in the recipient and the donor.
Definitions
Patients who underwent dCBT in first or second remission of acute myelogenous leukemia (AML), in first remission of acute lymphoblastic leukemia (ALL) and malignant lymphoma (ML), or in the chronic phase of chronic myelogenous leukemia (CML) and refractory anemia of MDS were classified as standard risk. All others were classified as advanced risk.
Neutrophil recovery was defined as achievement of an absolute neutrophil count (ANC) of !500/mL for 3 consecutive days; platelet recovery was defined as a count of !50,000/mL without transfusion support. Primary engraftment failure was defined as the absence of donor-derived myeloid cells on the day of death or day þ60 in patients surviving beyond day þ2þ8 after dCBT, or when a second stem cell transplantation was required for donor-derived myeloid recovery. Diagnosis and clinical grading of acute GVHD (aGVHD) were performed according to established criteria [16] . Relapse was defined as recurrence of the underlying hematologic malignancy. TRM was defined as death during a continuous remission. Diseasefree survival (DFS) was defined as survival in a state of continuous remission. Event-free survival (EFS) was defined as survival in a state of remission without engraftment failure.
Statistical Analyses
The primary endpoint of this study was 1-year EFS; secondary endpoints were neutrophil and platelet engraftment, incidence of aGVHD and chronic GVHD (cGVHD), toxicity within 28 days, incidence of TRM and relapse, DFS, and overall survival (OS). The expected and threshold EFS at 1 year were estimated as 60% and 40%, respectively. With a statistical power of 90% and a 1-sided type I error of 5%, the number of eligible patients required for this study was calculated as 56 using a binomial analysis method. The projected sample size was 70 patients, assuming that 20% of patients would be ineligible. Primary endpoint analysis was performed using the Kaplan-Meier method to calculate the probability of EFS. Treatment was considered effective if the lower limit of the 90% confidence interval (CI) exceeded the threshold EFS (ie, 40%).
Cumulative incidence curves were used in a competing-risks setting to calculate the probabilities of neutrophil and platelet recovery, aGVHD, cGVHD, relapse, and TRM. For neutrophil and platelet recovery, death before recovery was the competing event; for GVHD, death without GVHD and relapse was the competing events; for relapse, death without evidence of relapse was the competing event; and for TRM, relapse was the competing event. OS, DFS, and EFS were calculated by the Kaplan-Meier method. The log-rank test was used for univariate comparisons. Variables found to affect outcome with a P value <.20 on univariate analyses were selected for the multivariate analyses. Variables were selected in a backward stepwise manner with a variable retention criterion of P < .05 for the final model. The Wilcoxon signed-rank test was used to evaluate the effect of cell dose and HLA compatibility on engraftment of a predominant single CB unit, and the McNemar test was used for evaluation of categorical factors. The median duration of follow-up of survivors was 41 months (range, 12 to 57.4 months). Results are reported as of March 2011. Calculations were performed using Stat View J version 5.0 and Stata version 11.1 (StataCorp, College Station, TX).
RESULTS

Patient and Graft Characteristics
A total of 70 patients were enrolled between April 2006 and January 2010. Nine patients did not undergo dCBT, 7 because of disease progression and 2 because they received a graft from another source. Patient and graft characteristics are summarized in Table 1 . The 61 patients who underwent dCBT included 8 females and 53 males, with a median age of 37 years (range, 10 to 54 years) and a median body weight of 70.5 kg (range, 50.1 to 129.8 kg). Antibodies against CMV were detected in 75.4% of the patients; CMV antibody was not tested in 3 patients. The underlying malignancy was AML in 30 patients, ALL in 17 patients, CML in 6 patients, MDS in 5 patients, and ML in 3 patients. Disease status at dCBT was classified as standard risk in 27 patients and as advanced risk in 34 patients. /kg at dCBT because of weight gain. Because 1.47 rounded off to 1 decimal place is 1.5, we decided to include this case in the analyses.
HLA matching for HLA-A, -B, and -DRB1 low-and highresolution types between recipients and donors and between donors is described in Table 1 . When the graft with fewest HLA mismatches was counted for each recipient, only 2 patients (3%) received a graft that contained at least 1 unit in which HLA-A, -B, and -DRB1 were matched at a lowresolution level to the recipient; 21 patients (34%) received a graft with at least 1 unit 5/6 HLA-matched to the recipient; and 38 patients (62%) received a graft with both units 4/6 HLA-matched to the recipient. Among the 58 patients with HLA-DRB1 typed by high-resolution DNA typing, 2 patients (3%) received a graft that contained at least one 6/6 HLAmatched unit, 17 (29%) received at least one 5/6 HLAmatched unit, 31 (53%) received at least one 4/6 HLA-matched unit, 8 (14%) received at least one 3/6 HLAmatched unit. Three, 17, and 4 patients received a graft with both units 5/6, 4/6, and 3/6 HLA-matched to the recipient, respectively. The units were 6/6 HLA-Ae, -Be, and DRB1ematched at low resolution to each another in 1 patient, 5/6 matched in 14 patients, 4/6 matched in 13 patients, 3/6 matched in 23 patients, and 2/6 matched in 10 patients. When HLA was typed by HLA-A and -B lowresolution and -DRB1 high-resolution typing, the units were 5/6 matched to each other in 8 patients, 4/6 matched in 12 patients, 3/6 matched in 20 patient, 2/6 matched in 15 patients, and 1/6 matched in 6 patients.
Survival
The median follow-up for survivors (n ¼ 32) was 41 months. EFS at 1 year was 48% (90% CI, 37%-58%) ( Figure 1A) . One-year EFS at 1 year was 67% (95% CI, 46%-81%) in patients with standard risk and 32% (95% CI, 18%-48%) in patients with advanced risk at dCBT, and 3-year EFS was 67% (95% CI, 46%-81%) in patients with standard risk and 29% (95% CI, 15%-45%) in those with advanced risk (P ¼ .023) ( Figure 1B) . One-year DFS was 49% (95% CI, 36%-61%), and 1-year OS was 57% (95% CI, 44%-69%). Three-year DFS was 47% (95% CI, 34%-59%), and 3-year OS was 54% (95% CI, 40%-65%). Disease status at transplantation was the sole prognostic factor affecting EFS (relative risk [RR], 2.71; P ¼ .011). No other variable considered had a significant effect on EFS.
Toxicity Within 28 Days after dCBT
Toxicities occurring within 28 days after dCBT were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. The most frequent grade 3-4 toxicity was infection, occurring in 43 of 61 patients (70.5%); other grade 3-4 toxicities included nausea/vomiting (17 patients; 27.9%), oral mucosa lesions (16; 26.2%), diarrhea (13; 21.3%), cardiac events (6; 9.8%), liver toxicity (6; 9.8%), bleeding (5; 8.2%), neurologic events (3; 4.9%), renal/urinary events (3; 4.9%), skin toxicity (3; 4.9%), lung toxicity (2; 3.3%), and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (1; 1.6%). Grade 4 toxicities involving infections were seen in 5 patients (8.2%), and those involving the heart occurred in 2 patients (3.3%). Other grade 4 toxicities included bleeding and neurologic, lung, and liver toxicities, which were seen in 1 patient each.
Hematopoietic Recovery and Chimerism
The cumulative incidence of neutrophil recovery was 67% (95% CI, 53%-77%) at day þ28 and 85% (95% CI, 73%-92%) at day þ50 (Figure 2) . The cumulative incidence of platelet recovery at day þ180 was 77% (95% CI, 66%-89%). The median time to neutrophil recovery was 25 days (range, 17 to 49 days). A greater degree of HLA matching between the 2 units (!3 antigen mismatches with increased risk of no neutrophil recovery compared with 2 antigen mismatches; RR, 0.53; P ¼ .023) was the sole risk factor affecting neutrophil recovery.
Three patients (5%) died too early to allow evaluation of engraftment (2 patients on day þ7 and 1 patient on day þ12). Failure of primary engraftment occurred in 7 patients; 6 of these 7 patients underwent a second transplantation (single-unit CBT in 3, autologous peripheral blood stem cell transplantation in 2, haploidentical peripheral blood stem cell transplantation in 1) between day þ27 and day þ49. Only 1 of these patients survived beyond 1 year after dCBT. All but 1 of the 51 patients with donor engraftment had complete chimerism derived from a single donor (median, 100%; range, 91.2% to 100%) by day 30 after dCBT. One patient demonstrated mixed chimerism from both donors (81.6% and 11.5%) at day þ30, but this changed to complete chimerism of single-donor origin by day þ60.
Predicting Factors Responsible for Unit Dominance
The degree of HLA disparity in the host-versus-graft (HVG) direction was associated with unit dominance ( Table 2 ). Twenty of the 51 patients with donor engraftment received 2 units with varying degrees of HLA disparity (HLA-A, -B, and -DR antigen-level typing). Of these, the unit that was better HLA-matched to the recipient engrafted in 15 patients, whereas the more poorly matched unit predominated in 5 patients (P ¼ .0218). Twenty-seven of 49 engrafted patients typed by HLA-A or -B antigen-level and -DRB1 highresolution typing received 2 units with different degrees of HLA disparity; of these, the better-matched unit engrafted in 21 patients (P ¼ .0056).
There was no correlation between unit dominance and cell dose (cryopreserved TNCs, P ¼ .4589; cryopreserved CD34 þ cells, P ¼ .3823; cryopreserved granulocyte macrophage colony-forming units (GM-CFU), P ¼ .6854; infused TNCs, P ¼ .6114; infused CD34 þ cells, P ¼ .3875; infused GM-CFU, P ¼ .8405). Other factors, including sex match (P ¼ .7003), ABO match (P ¼ 1.0), order of infusion (P ¼ .4838), and graft viability (P ¼ .6152), were not associated with unit dominance.
GVHD aGVHD developed in 33 of the 61 patients (54%), classified as grade I in 18 patients, grade II in 11, grade III in 3, and grade IV in 1 (25% grade II-IV and 7% grade III-IV). cGVHD was observed in 18 of the 50 evaluable patients who survived for >100 days, and was extensive in 9 patients. The cumulative incidence of grade II-IV aGVHD was 25% (95% CI, 15%-37%), and that of cGVHD at 1 year was 32% (95% CI, 20%-44%) ( Figure 3A and B) . No risk factors for the development of grade II-IV aGVHD were identified in univariate and multivariate analyses including HLA disparities (P ¼ .327).
Relapse
Relapse occurred in 15 patients, between 57 and 573 days (median, 135 days) after dCBT. The cumulative incidence of relapse at 1 year was 23% (95% CI, 13%-34%) ( Figure 3C ).
Seven of 17 patients with ALL relapsed, compared with only 8 of 41 patients with myeloid malignancies (AML, 6 of 29; CML, 1 of 6; MDS, 1 of 6). In terms of disease status at transplantation, relapse occurred in 4 of 27 patients with standard risk and in 11 of 34 patients with advanced risk. No risk factors for relapse were identified by univariate and multivariate analyses, including disease status at CBT (P ¼ .291) and HLA disparities (P ¼ .156).
TRM and Cause of Death
The cumulative incidence of TRM was 15% (95% CI, 7%-25%) at day þ100 and 28% (95% CI, 17%-39%) at 1 year ( Figure 3D ). No risk factors for TRM were identified on univariate and multivariate analyses. The causes of death are listed in Table 3 . Disease progression was the leading cause of death. Of the 29 patients who died between 7 and 1368 days (median, 188 days) after dCBT, 15 died from causes other than relapse: graft failure in 5 (of whom 3 died from infection and 1 died from hepatic veno-occlusive disease after a second transplantation), infection without graft failure in 2, organ failure in 3, acute respiratory distress syndrome/interstitial pneumonia in 3, and cGVHD and bleeding in 1.
DISCUSSION
The present study is the first reported analysis of dCBT in Japan. In this multicenter Phase II study, greater HLA disparities between recipient and donor and between each of the 2 units were found compared with those reported in previous studies of dCBT, because we selected the 4-6/6 HLA- Figure 1 . Kaplan-Meier analysis of EFS in patients with dCBT after myeloablative conditioning (A) and according to disease status (B). Patients with standard risk had significantly better posttransplantation survival than those with advanced risk (P ¼ .023, log-rank test). matched CB unit for the recipient by matching at the lowresolution DNA typing level of HLA-A, -B, and -DRB1, with no consideration of uniteunit match. The lower limit of the 90% CI did not exceed the threshold EFS by 3% in primary endpoint analyses. The threshold and expected EFS was estimated prior to study initiation according to survival results of single-unit CBT (EFS of 40% at 1 year; unpublished data, Japan Cord Blood Bank Network, 2005) and dCBT [17] (EFS of 64% at 1 year) for adults. In these studies, 21% and 36% of patients were received CBT in advanced-risk disease status, respectively, whereas 54% of patients in this study were in advanced-risk disease status at the time of dCBT. Our survival data are comparable to earlier reports of dCBT after myeloablative conditioning [10] [11] [12] [13] [14] [15] ; thus, we can confirm that dCBT after myeloablative conditioning is a promising alternative option for adults and large children with hematologic malignancies who need HSCT but do not have a suitable related/unrelated donor or an adequate single-unit CB graft. We have also shown that HLA disparity in the HVG direction helps determine which unit was engrafted. These data may provide clinically useful information to aid in the selection of CB units for dCBT.
Our cumulative incidence of neutrophil engraftment of 85% and median time to neutrophil recovery of 25 days are comparable to previously reported values for dCBT with myeloablative conditioning (ie, cumulative incidence of neutrophil engraftment, 80%-94%; median time to neutrophil recovery, 23-25 days) [10, [12] [13] [14] [15] . The degree of HLA disparity between the 2 units was the sole factor associated with neutrophil engraftment. On the other hand, uniteunit HLA match reportedly had no significant effect on sustained engraftment and speed of neutrophil recovery [18] . Further studies are needed to investigate the influence of cross-immunologic reactions between the 2 units on neutrophil engraftment.
Our results are in agreement with previously reported data, which indicated that 1 CB unit becomes predominant and supports sustained hematopoiesis in dCBT. The parameters that determine unit dominance have not yet been elucidated. In our analysis, only the degree of HLA disparity in the HVG direction was correlated with unit dominance. To our knowledge, this is the first report suggesting that hostversus-graft immune reactions play a role in determining the engrafting unit. There was no correlation between dominance and the doses of TNCs, CD34
þ cells, and GM-CFU or ABO, sex mismatch, cell viability, or order of infusion. Previous reports have implied that CD3 þ , GM-CFU, and CD34 þ cell doses and the viability of CD34 þ cells were associated with the unit dominance [14, [18] [19] [20] [21] , and that the presence of graft-versus-graft reactions mediated by CD8 þ T cells expanding from the dominant unit play a critical role Analyses were performed with the Wilcoxon signed-rank test. in rejecting the other unit [22] . We could not verify the importance of CD3 þ cell count and CD34 þ cell viability because we did not assay these parameters in our study. Furthermore, there are reports concerning the effect of preformed donor-specific anti-HLA antibodies on graft failure or unit loss in dCBT [23] . Whether the unit dominance is influenced by immune reactions between the units or between the recipient and the units still remains to be determined. On the other hand, the use of 2 units might simply give the recipient a better chance of having a unit with a sufficiently high potential for engrafting. Further study is warranted. In single-unit CBT, the doses of TNCs and CD34 þ cells at cryopreservation or at infusion have important effects on survival [7] [8] [9] . According to a recent report by Sanz et al. [24] , in adults with AML, a low dose of TNCs (<2 Â 10 7 /kg) at infusion was the only significant factor associated with lower leukemia-free survival (LFS at 4 years; <2.0Â10 7 /kg versus !2.0Â 10 7 /kg, 25% versus 75%) [24] . Based on the foregoing results, the suggested dose of TNC at cryopreservation should not be <2.5 Â 10 7 /kg, given the anticipated cell loss of approximately 20% [25, 26] . In this study, the TNC dose in the large unit was <2.5Â10 7 /kg in all recipients and further that was <2.0Â10 7 /kg in 38 patients (62%). Because dCBT was performed, these patients had a chance to undergo stem cell transplantation and achieved an EFS of 46% at 3 years, which is similar to or better than the survival seen with single-unit CBT [24, 27] . The extent of the benefit has not been demonstrated by a matched-cohort analysis or prospective randomized trial, however. The reported incidence of grade II-IV aGVHD is higher in patients undergoing dCBT compared with those undergoing single-unit CBT, although the frequency of severe-grade aGVHD is comparable in the 2 groups [28] . According to McMillan et al. [28] , the increased risk for aGVHD after dCBT may be the result of a higher dose of T cells in the grafts when 2 units are used and/or a graft-versus-graft effect, although the precise mechanism is not clear. In our study, grade II-IV aGVHD developed in 25% of the patients and grade III-IV aGVHD occurred in 7%. The fact that the incidence of grade II-IV aGVHD seems to be lower than that reported by others (eg, 37%-65% incidence of II-IV aGVHD in dCBT with myeloablative conditioning), and the incidence of severe aGVHD was comparable [10] [11] [12] [13] [14] [15] , despite greater HLA disparities between recipients and donors and between the 2 units in our study. Our lower incidence of aGVHD is likely related to the different conditioning and GVHD prophylaxis regimens compared with previous studies [10] [11] [12] [13] [14] [15] 28] . The infused T cell doses in our study may have an influence on this finding, although the infused TNC dose was similar to that used in previous studies [10, 12, 13, 28] . Ethnic differences also may contribute to these findings, as has been reported by Morishima et al. [29] and Oh et al. [30] Further studies with larger numbers of patients are needed to identify the effect of these factors, as well as of HLA matching, on GVHD.
Our relapse rate at 1 year of 23% is higher than reported in other studies (eg, relapse incidence of 15% at 5 years by Brunstein et al. [13] , 19% at 5 years by Verneris et al. [12] , 19% by Kang et al. [15] , and 20% at 2 years by Kanda et al. [14] for dCBT after myeloablative conditioning). The relapse rate is reportedly lower in dCBT recipients compared with singleunit CBT recipients. Verneris et al. [12] analyzed the outcomes of CBT for acute leukemia and showed a significantly lower relapse rate among patients who received dCBT in remission compared with patients who underwent singleunit CBT (16% versus 31%). Rodrigues et al. [11] also reported a lower risk for relapse in patients with chronic lymphoid malignancies who underwent dCBT (13% versus 38% at 1 year). Although the precise mechanism is not known, these data suggest an enhanced graft-versus-leukemia effect in dCBT. The incidence of grade II-IV aGVHD in the present study was not higher than that reported in previous studies, and more patients with advanced risk at the time of dCBT were included compared with other reports [12] [13] [14] [15] , which might reflect the somewhat higher relapse rate.
The incidence of TRM (28%) in the present study was comparable with that reported in other studies of dCBT (29%-31%) [10] [11] [12] [13] [14] [15] . Fifteen of the 29 patients who died did so from causes not related to relapse. Nine patients died within 100 days after dCBT, and all but 1 death were related to transplantation resulting mainly from graft failure. In addition, the major cause of death after day 100 was relapse. To improve survival, strategies to enhance engraftment and reduce relapse are required.
We demonstrated that survival outcomes and the incidence of engraftment, GVHD, relapse, and TRM seem to be comparable with that in other reports of dCBT and with our historical data from single-unit CBT. Interestingly, we also demonstrated that HLA disparity in the HVG direction has an impact on determining the grafting unit. Further studies with larger numbers of patients will be needed to clarify this and to develop guidelines for selection of units for dCBT.
In conclusion, we believe that myeloablative dCBT can be a feasible and effective alternative option for patients with hematologic malignancies who need HSCT but have neither a suitable related/unrelated donor nor an adequate singleunit CB graft available. To validate the "double-cord" effect that is generally assumed to reduce the incidence of relapse, increase the incidence of aGVHD, and improve survival, a matched cohort study with a larger number of patients or a prospective randomized study (if possible), is needed.
